

FDA rejects Achieve Life Sciences application for cytisinicline tied to manufacturing issues, with NDA resubmission planned in Q4 2026.
You can purchase shares of Achieve Life Sciences Inc (NASDAQ:ACHV) through any online brokerage.
Other companies in Achieve Life Sciences Inc’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Achieve Life Sciences Inc has a consensus price target of $14.90.
The stock price for Achieve Life Sciences Inc (NASDAQ: ACHV) is $6.71 last updated November 9, 2026 at 5:23 PM EST.
There are no upcoming dividends for Achieve Life Sciences Inc.
Achieve Life Sciences Inc does not have any upcoming earnings scheduled.
There is no upcoming split for Achieve Life Sciences Inc.
Achieve Life Sciences Inc is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.